Sutro Biopharma (STRO) Total Non-Current Liabilities (2017 - 2025)

Sutro Biopharma (STRO) has 9 years of Total Non-Current Liabilities data on file, last reported at $304.6 million in Q4 2025.

• For the quarter ending Q4 2025, Total Non-Current Liabilities fell 10.65% year-over-year to $304.6 million; the trailing twelve-month figure through Dec 2025 stood at $304.6 million (down 10.65% YoY), and the FY2025 full-year result was $304.6 million, down 10.65% from the prior year.
• Total Non-Current Liabilities climbed to $304.6 million in Q4 2025, from $295.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $345.5 million in Q1 2025 to a low of $50.6 million in Q1 2021.
• A 5-year average of $222.0 million and a median of $292.8 million in 2025 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities declined 29.44% in 2021 and soared 242.94% in 2022, its largest moves.
• Tracing STRO's Total Non-Current Liabilities over 5 years: stood at $88.7 million in 2021, then soared by 113.96% to $189.8 million in 2022, then jumped by 68.3% to $319.4 million in 2023, then grew by 6.74% to $340.9 million in 2024, then retreated by 10.65% to $304.6 million in 2025.
• Business Quant data shows STRO's Total Non-Current Liabilities at $304.6 million in Q4 2025, $295.2 million in Q3 2025, and $292.8 million in Q2 2025.